-
![SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS](/abs-image/US/2013/04/04/US20130085141A1/abs.jpg.150x150.jpg)
21.发明申请SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINE SULFONAMIDES AS CALCIUM CHANNEL BLOCKERS 有权取代的甲氧基吡咯并[1,2-a]吡啶磺酰胺作为钙通道阻断剂公开(公告)号：US20130085141A1
公开(公告)日：2013-04-04
申请号：US13627536
申请日：2012-09-26
Applicant: ABBVie Inc.
Inventor： Tao Li , Sachin V. Patel , Richard J. Perner , John T. Randolph , Michael R. Schrimpf , Kevin R. Woller , Zhiren Xia , Qingwei Zhang
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: The present application relates to: (a) compounds of Formula (I): and salts thereof, wherein Z′, Z″, L2, G2, R1, and R2 are as defined in the specification; (b) compositions comprising such compounds and salts; and (c) methods of use of such compounds, salts, and compositions, particularly use as calcium channel blockers.
Abstract translation: 本申请涉及：（a）式（I）化合物及其盐，其中Z'，Z“，L2，G2，R1和R2如说明书中所定义; （b）包含这些化合物和盐的组合物; 和（c）使用这些化合物，盐和组合物的方法，特别是用作钙通道阻滞剂。
-
公开(公告)号：US20240000792A1
公开(公告)日：2024-01-04
申请号：US18463183
申请日：2023-09-07
Applicant: Calico Life Sciences LLC , AbbVie Inc.
Inventor： Kathleen Ann Martin , Carmela Sidrauski , Jennifer M. Frost , Yunsong Tong , Xiangdong Xu , SeungWon Chung , Qingwei Zhang , Lei Shi , Kathleen J. Murauski , Michael J. Dart , John T. Randolph
IPC: A61K31/538 , A61K31/343 , A61K31/353 , A61K31/357 , A61K31/36 , A61K31/404 , A61K31/4045 , A61K31/472 , A61K45/06 , C07C235/22 , C07D209/08 , C07D209/42 , C07D217/16 , C07D265/36 , C07D307/85 , C07D311/66 , C07D317/46 , C07D319/20 , C07D405/12 , C07D413/06 , C07D413/12 , C07D493/04
CPC classification number: A61K31/538 , A61K31/343 , A61K31/353 , A61K31/357 , A61K31/36 , A61K31/404 , A61K31/4045 , A61K31/472 , A61K45/06 , C07C235/22 , C07D209/08 , C07D209/42 , C07D217/16 , C07D265/36 , C07D307/85 , C07D311/66 , C07D317/46 , C07D319/20 , C07D405/12 , C07D413/06 , C07D413/12 , C07D493/04
Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
-
公开(公告)号：US20220251123A1
公开(公告)日：2022-08-11
申请号：US17446807
申请日：2021-09-02
Applicant: Calico Life Sciences LLC , AbbVie Inc.
Inventor： Kathleen Ann Martin , Carmela Sidrauski , Michael J. Dart , Jennifer M. Frost , Yunsong Tong , Xiangdong Xu , Lei Shi , Kathleen Murauski , Marina Pliushchev , Brian S. Brown , Eric Voight , John T. Randolph
IPC: C07F9/12
Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
-
公开(公告)号：US20200347043A1
公开(公告)日：2020-11-05
申请号：US16863747
申请日：2020-04-30
Applicant: Calico Life Sciences LLC , AbbVie Inc. , SYGNATURE DISCOVERY LIMITED
Inventor： Kathleen Ann Martin , Carmela Sidrauski , Lei Shi , Kathleen J. Murauski , Xiangdong Xu , Yunsong Tong , John T. Randolph , Michael J. Dart , Hanae Benelkebir , Steven Edeson , Kathryn Starbuck
IPC: C07D413/12 , A61P25/28 , A61K45/06 , A61K31/422 , C07D405/12 , A61K31/4155 , A61K31/403 , C07D311/24 , A61K31/353 , C07D311/22 , A61K31/4433 , A61K31/4245 , C07C235/36 , A61K31/165 , C07D493/08 , A61K31/4025 , C07C235/40 , C07D405/06 , A61K31/397 , C07D407/12 , C07D271/10 , C07D471/04 , A61K31/437
Abstract: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
-
公开(公告)号：US20200338208A1
公开(公告)日：2020-10-29
申请号：US16850866
申请日：2020-04-16
Applicant: AbbVie Inc.
Inventor： Michael J. McPherson , Adrian D. Hobson , Martin E. Hayes , Christopher C. Marvin , Diana Schmidt , Wendy Waegell , Christian Goess , Jason Z. Oh , Axel Hernandez, JR. , John T. Randolph
Abstract: Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.
-
Patent Agency Ranking
公开(公告)号：US10053474B2
公开(公告)日：2018-08-21
申请号：US15588037
申请日：2017-05-05
Applicant: AbbVie Inc.
Inventor： Jaclyn Chau , Hui-Ju J. Chen , David A. DeGoey , John Hartung , Nathan Ide , Vikram Kalthod , Allan C. Krueger , Yi-Yin Ku , Tongmei Li , John T. Randolph , Rolf Wagner , Geoff T. Halvorsen , Christopher C. Marvin , Eric Voight , Brian S. Brown , Steven R. Martinez , Anurupa Shrestha , Howard R. Heyman
IPC: A61K31/675 , C07F9/02 , C07F9/08 , C07F9/6512 , C07H19/10
CPC classification number: C07F9/08 , C07F9/6512 , C07H19/10
Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US10028937B2
公开(公告)日：2018-07-24
申请号：US15434789
申请日：2017-02-16
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean-Christophe C. Califano , William A. Carroll , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: A61K38/00 , C07K16/00 , A61K31/4184 , A61K31/454 , A61K31/4439 , A61K31/422 , A61K31/4418 , A61K31/4545 , A61K31/695 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/438 , A61K31/435
CPC classification number: A61K31/454 , A61K31/4178 , A61K31/4184 , A61K31/422 , A61K31/435 , A61K31/4355 , A61K31/438 , A61K31/4418 , A61K31/4439 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D491/113 , C07F7/02 , Y02P20/582
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
公开(公告)号：US20170057981A1
公开(公告)日：2017-03-02
申请号：US15254342
申请日：2016-09-01
Applicant: AbbVie Inc.
Inventor： Hui-Ju J. Chen , David A. DeGoey , John Hartung , Nathan Ide , Vikram Kalthod , Allan C. Krueger , Yi-Yin Ku , Tongmei Li , John T. Randolph , Rolf Wagner , Jaclyn Chau , Geoff T. Halvorsen , Christopher C. Marvin , Eric Voight
IPC: C07F9/08
CPC classification number: C07F9/08 , C07F9/6512 , C07H19/10
Abstract: The present invention features compounds effective in inhibiting active against Hepatitis C virus (“HCV”) polymerase. The invention also features processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Abstract translation: 本发明的特征在于有效抑制丙型肝炎病毒（“HCV”）聚合酶的活性的化合物。 本发明还涉及制备这些化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。
-
公开(公告)号：US20150218194A1
公开(公告)日：2015-08-06
申请号：US14683910
申请日：2015-04-10
Applicant: AbbVie Inc.
Inventor： Mary E. Bellizzi , David A. Betebenner , Jean C. Califano , Daniel D. Caspi , David A. DeGoey , Pamela L. Donner , Charles A. Flentge , Yi Gao , Charles W. Hutchins , Douglas K. Hutchinson , Tammie K. Jinkerson , Warren M. Kati , Ryan G. Keddy , Allan C. Krueger , Wenke Li , Dachun Liu , Clarence J. Maring , Mark A. Matulenko , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , John K. Pratt , John T. Randolph , Todd W. Rockway , Kathy Sarris , Michael D. Tufano , Seble H. Wagaw , Rolf Wagner , Kevin R. Woller
IPC: C07F9/6558 , C07D405/14 , C07D403/14 , C07D401/14 , C07D207/09 , C07D491/113 , C07D413/14 , C07D471/04 , C07C201/06 , C07D207/08 , C07D207/16 , C07D417/14
CPC classification number: C07F9/65583 , C07C33/26 , C07C201/06 , C07C205/19 , C07D207/08 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D471/04 , C07D491/113 , C07K5/06
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Abstract translation: 描述了有效抑制丙型肝炎病毒（“HCV”）复制的化合物。 本发明还涉及制备这种化合物的方法，包含这些化合物的组合物，以及使用这些化合物治疗HCV感染的方法。
-
公开(公告)号：US09006387B2
公开(公告)日：2015-04-14
申请号：US14180886
申请日：2014-02-14
Applicant: AbbVie, Inc.
Inventor： Rolf Wagner , John K. Pratt , Dachun Liu , Michael D. Tufano , David A. DeGoey , Warren M. Kati , Charles W. Hutchins , Pamela L. Donner , John T. Randolph , Christopher E. Motter , Lissa T. Nelson , Sachin V. Patel , Mark A. Matulenko , Ryan G. Keddy , Tammie K. Jinkerson , Todd W. Rockway , Clarence J. Maring , Douglas K. Hutchinson , Charles A. Flentge , David A. Betebenner , Kathy Sarris , Kevin R. Woller , Seble H. Wagaw , Jean C. Califano , Wenke Li , Daniel D. Caspi , Mary E. Bellizzi , Yi Gao , Allan C. Krueger
IPC: C07K16/00 , A61K38/00 , C07K5/06 , C07D401/14 , C07D403/14 , C07D417/14 , C07C33/26 , C07C205/19
CPC classification number: C07F9/65583 , C07C33/26 , C07C201/06 , C07C205/19 , C07D207/08 , C07D207/09 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D453/00 , C07D471/04 , C07D491/113 , C07K5/06
Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
-
-
-
-
-
-
-
-
-
Search Results
48
records
(took 0.044 seconds)
